News

NESP, a long-acting erythropoiesis stimulating agent, was initially approved in July 2007. NESP is highly recognized for its safety and efficacy for treating anemia of chronic kidney disease

The acquisition positions Charles River as a full service, early-stage contract research organization (CRO), with integrated in vitro and in vivo capabilities from target discovery through preclinical development.

NCCN ORP vice president Diane Paul said this grant from Astellas and Medivation gives investigators at NCCN Member Institutions a remarkable opportunity to study the effectiveness of enzalutamide

Under the option agreement, the company has received a $1m, non-refundable option fee. If not exercised, the option that is subject to certain contingencies will expire on 30

The injection is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. Adenosine features the company’s PreventIV Measures packaging and labeling, designed

Additionally, Eisai has assigned the patent right for its metabolic enzyme inhibitor E7727 to Otsuka. As part of the deal, Eisai will transfer to Otsuka its rights to

The announcement means a streamlining of the complex process of clinical research studies, making the setting up of such studies faster and easier by reducing bureaucracy and duplication.

This collaboration will enable Lundbeck’s researchers to take decisive steps towards new and better treatment of the debilitating and life-long brain disease that is schizophrenia. This joint project

Distinguished by a novel chimeric gene segment design, the Trianni platform provides Takeda with easy access to a complete human antibody repertoire that has been optimized for the